Ipca Laboratories Ltd
IPCALAB
Company Profile
Business description
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
Contact
125, Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
INDT: +91 2262105000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
22,841
Stocks News & Analysis
stocks
Signs of a turnaround for undervalued ASX share
Market likes the payoff from early efforts at reining in costs.
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,825.10 | 20.90 | 0.24% |
CAC 40 | 8,178.54 | 14.43 | 0.18% |
DAX 40 | 22,513.42 | 98.60 | -0.44% |
Dow JONES (US) | 44,546.08 | 165.35 | -0.37% |
FTSE 100 | 8,732.46 | 32.26 | -0.37% |
HKSE | 22,620.33 | 805.96 | 3.69% |
NASDAQ | 20,026.77 | 81.13 | 0.41% |
Nikkei 225 | 39,149.43 | 312.04 | -0.79% |
NZX 50 Index | 12,989.18 | 83.20 | 0.64% |
S&P 500 | 6,114.63 | 0.44 | -0.01% |
S&P/ASX 200 | 8,555.80 | 15.80 | 0.19% |
SSE Composite Index | 3,346.72 | 14.24 | 0.43% |